Pingyangmycin stimulates apoptosis in human hemangioma-derived endothelial cells through activation of the p53 pathway.
Jun-Bo Tu,Quan-Yan Li,Fei Jiang,Xiao-Yi Hu,Rui-Zhao Ma,Qiang Dong,Hao Zhang,Parukjan Pattar,Shi-Xian Li
DOI: https://doi.org/10.3892/mmr.2014.2174
IF: 3.423
2014-01-01
Molecular Medicine Reports
Abstract:Pingyangmycin (also known as Bleomycin A5) is produced by Streptomyces verticillus var. pingyangensis n.sp., and has anti-tumor activities against a variety of tumor cells. The aim of the present study was to determine the molecular mechanism(s) underlying the therapeutic effects of pingyangmycin against infantile hemangiomas. Human hemangioma-derived endothelial cells (HemECs) were treated with pingyangmycin at varying concentrations (100, 200 or 300 mu g/ml), and the morphological changes and apoptosis levels were assessed. The gene expression changes were determined by cDNA microarray technology. Transmission electron microscopy examination revealed that the pingyangmycin-treated HemECs exhibited typical apoptotic characteristics, including chromatin condensation and the formation of apoptotic bodies. Annexin-V staining demonstrated that pingyangmycin caused a significant and dose-dependent induction of apoptosis in the HemECs. In the pingyangmycin-treated HemECs, 4,752 genes demonstrated at least 2-fold expression changes at the mRNA level. Quantitative polymerase chain reaction confirmed that pingyangmycin significantly upregulated the expression of p53, p53-induced protein with death domain, Bax, p53 upregulated modulator of apoptosis and p53 inducible gene 3, and down-regulated the expression of murine double minute 2. The data demonstrated that the pro-apoptotic activity of pingyangmycin against infantile hemangiomas involves p53 pathway activation.